Product
DSP-7888
Aliases
adegramotide and nelatimotide, DSP-7888 Dosing Emulsion, Ombipepimut-S (adegramotide and nelatimotide)
3 clinical trials
1 abstract
14 indications
Indication
Renal Cell CarcinomaIndication
Bladder CancerIndication
Primary Peritoneal CancerIndication
Platinum-resistant Ovarian Cancer (PROC)Indication
Ovarian CancerIndication
Fallopian tube cancerIndication
Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromesIndication
Glioblastoma MultiformeIndication
MelanomaIndication
Pancreatic CancerIndication
SarcomaIndication
GlioblastomaIndication
NSCLCClinical trial
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2022-10-19
Clinical trial
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2018-08-01
Clinical trial
A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)Status: Completed, Estimated PCD: 2021-08-30